We are live on
!
Find out more
VCM
Vision Capital Management Portfolio holdings
AUM
$792M
1-Year Est. Return
18.17%
This Fund
S&P 500
This Quarter
Est. Return
+4.99%
1 Year Est. Return
+18.17%
3 Year Est. Return
+56.41%
5 Year Est. Return
+57.55%
10 Year Est. Return
+256.21%
AUM
$381M
AUM Growth
+$21.5M
(+6%)
Cap. Flow
+$35.7M
Cap. Flow
% of AUM
9.36%
Top 10 Holdings %
Top 10 Hldgs %
46.93%
Holding
85
New
5
Increased
18
Reduced
50
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$31.1M |
| 2 |
Amgen
AMGN
|
+$2.87M |
| 3 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$2.3M |
| 4 |
iShares Core S&P 500 ETF
IVV
|
+$1.33M |
| 5 |
NEWR
New Relic, Inc.
NEWR
|
+$1.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.44M |
| 2 |
Apple
AAPL
|
+$1.31M |
| 3 |
CVS Health
CVS
|
+$710K |
| 4 |
Visa
V
|
+$703K |
| 5 |
Amazon
AMZN
|
+$259K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 11.97% |
| 2 | Consumer Discretionary | 10.16% |
| 3 | Industrials | 7.59% |
| 4 | Financials | 7.58% |
| 5 | Communication Services | 6.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
51
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.37M | 0.36% |
10,482
+113
| +1% | +$14.6K |
|
52
Williams-Sonoma
WSM
$27.6B
| $1.29M | 0.34% |
39,586
+390
| +1% | +$11.2K |
|
53
Colgate-Palmolive
CL
$73.6B
| $1.21M | 0.32% |
16,860
+15
| +0.1% | +$1.06K |
|
54
Accenture
ACN
$94.3B
| $1.19M | 0.31% |
6,438
-33
| -0.5% | -$5.93K |
|
|
55
Berkshire Hathaway Class B
BRK.B
$1.07T
| $1.11M | 0.29% |
5,214
-50
| -0.9% | -$10.3K |
|
56
United Parcel Service
UPS
$96B
| $1.09M | 0.29% |
10,570
+221
| +2% | +$23K |
|
57
VF Corp
VFC
$6.72B
| $973K | 0.26% |
11,142
-585
| -5% | -$50.4K |
|
58
Lowe's Companies
LOW
$119B
| $924K | 0.24% |
9,153
-161
| -2% | -$17K |
|
|
NEWR
59
DELISTED
New Relic, Inc.
NEWR
| $908K | 0.24% |
+10,495
| New | +$1.04M |
|
60
Qualcomm
QCOM
$179B
| $858K | 0.23% |
11,280
-774
| -6% | -$56.7K |
|
61
Eli Lilly
LLY
$1.07T
| $819K | 0.21% |
7,396
| – | – |
|
|
SCHR
62
Schwab Intermediately-Term US Treasury ETF
SCHR
$13.3B
| $736K | 0.19% |
26,770
+16,846
| +170% | +$455K |
|
63
Boeing
BA
$167B
| $725K | 0.19% |
1,991
| – | – |
|
64
JPMorgan Chase
JPM
$947B
| $715K | 0.19% |
6,394
| – | – |
|
65
US Bancorp
USB
$98.9B
| $697K | 0.18% |
13,305
| – | – |
|
66
iShares Russell 1000 ETF
IWB
$47.7B
| $642K | 0.17% |
3,943
| – | – |
|
67
Chevron
CVX
$378B
| $536K | 0.14% |
4,306
| – | – |
|
68
Wells Fargo
WFC
$264B
| $511K | 0.13% |
10,799
-190
| -2% | -$8.88K |
|
69
Watsco Inc
WSO
$15B
| $430K | 0.11% |
2,631
-57
| -2% | -$8.95K |
|
70
iShares Morningstar Growth ETF
ILCG
$3.09B
| $342K | 0.09% |
8,925
| – | – |
|
71
Schwab International Equity ETF
SCHF
$65.9B
| $337K | 0.09% |
21,002
+3,310
| +19% | +$52.4K |
|
|
72
Berkshire Hathaway Class A
BRK.A
$1.07T
| $318K | 0.08% |
+100
| New | +$31.1M |
|
73
Haverty Furniture Companies
HVT
$406M
| $318K | 0.08% |
18,682
| – | – |
|
74
Intel
INTC
$462B
| $280K | 0.07% |
5,852
+811
| +16% | +$40.2K |
|
75
ExxonMobil
XOM
$642B
| $278K | 0.07% |
3,628
-199
| -5% | -$15.4K |
|
Similar funds
AI
M
AWG
SC
AVLSA
AT
MTWSIF
VH
Vision Capital Management's Q2 2019 Portfolio in Review
As of Q2 2019, Vision Capital Management held 85 positions worth $381M, up 6% from $360M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Vision Capital Management deployed $35.7M of net new capital in Q2 2019, opening 5 new positions and adding to 18 existing holdings. Its largest new stake was Berkshire Hathaway Class A: 100 shares worth $318K.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 12% a quarter earlier, followed by Consumer Discretionary and Industrials.
On the sell side, the largest reduction was Apple, an estimated $1.31M trimmed.
- Vision Capital Management's largest Q2 2019 buy was Berkshire Hathaway Class A: 100 shares worth $318K.
- Vision Capital Management added most to Amgen in Q2 2019, an estimated $2.87M increase.
- Vision Capital Management's biggest Q2 2019 reduction was Apple, cutting an estimated $1.31M.
- Vision Capital Management fully exited Allergan plc in Q2 2019, selling an estimated $2.44M.
- Vision Capital Management's ten largest holdings make up 47% of its $381M portfolio in Q2 2019.
- Vision Capital Management opened 5 new positions and closed 1 in Q2 2019.
- Vision Capital Management's portfolio value rose 6% quarter-over-quarter to $381M.
Based on Vision Capital Management's 13F filing for Q2 2019, filed 29 Jul 2019.